Join

Compare · BSX vs BVS

BSX vs BVS

Side-by-side comparison of Boston Scientific Corporation (BSX) and Bioventus Inc. (BVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BSX and BVS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX is the larger of the two at $71.85B, about 95.0x BVS ($756.0M).
  • BVS has been more active in the news (16 items in the past 4 weeks vs 12 for BSX).
  • BSX has more recent analyst coverage (25 ratings vs 14 for BVS).
MetricBSXBVS
Company
Boston Scientific Corporation
Bioventus Inc.
Price
-
-
Market cap
$71.85B
$756.0M
1M return
-
-
1Y return
-
-
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
12
16
Recent ratings
25
14
BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

BVS

Bioventus Inc.

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Latest BSX

Latest BVS